WST

WST

USD

West Pharmaceutical Services Inc. Common Stock

$286.940+8.560 (3.075%)

Precio en Tiempo Real

Healthcare
Medical Instruments & Supplies
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$278.380

Máximo

$287.875

Mínimo

$277.195

Volumen

0.41M

Fundamentos de la Empresa

Capitalización de Mercado

20.6B

Industria

Medical Instruments & Supplies

País

United States

Estadísticas de Negociación

Volumen Promedio

0.64M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $187.43Actual $286.940Máximo $348.9

Noticias Relacionadas

Analyst Upgrades

TD Cowen Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $350

TD Cowen analyst Brendan Smith initiates coverage on West Pharmaceutical Servs with a Buy rating and announces Price Target of $350.

Ver más
TD Cowen Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $350
Analyst Upgrades

Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs with a Equal-Weight and raises the price target from $275 to $325.

Ver más
Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325
PR Newswire

West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the...

Ver más
West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Analyst Upgrades

UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355

UBS analyst John Sourbeer maintains West Pharmaceutical Servs with a Buy and raises the price target from $320 to $355.

Ver más
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355
Analyst Upgrades

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $350

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs with a Overweight and raises the price target from $325 to $350.

Ver más
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $350
PR Newswire

West to Participate in Upcoming Investor Conferences

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it...

Analyst Upgrades

Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $390

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs with a Outperform and raises the price target from $350 to $390.

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.